Literature DB >> 2413460

Selection of unique antigenic variants of Newcastle disease virus with neutralizing monoclonal antibodies and anti-immunoglobulin.

R M Iorio, M A Bratt.   

Abstract

Monoclonal antibodies were used to isolate nonneutralizable antigenic variants in the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. It had been found that a large percentage of virus retains infectivity despite binding neutralizing antibody. This high persistent fraction of nonneutralized virus precluded the isolation of variants by the standard treatment with antibody alone. Rabbit anti-mouse immunoglobulin was used to reduce the percentage of virus that remains infectious despite the presence of bound antibody. This procedure made possible the isolation of variants of two distinct types: classical variants, not neutralized because they do not bind the antibody used to select them; and unique variants that, although still capable of binding the selecting antibody, are only slightly neutralized. The general applicability of this method for the isolation of antigenic variants in nonneutralizing epitopes is also discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413460      PMCID: PMC391319          DOI: 10.1073/pnas.82.20.7106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Antigenic drift in type A influenza virus: sequence differences in the hemagglutinin of Hong Kong (H3N2) variants selected with monoclonal hybridoma antibodies.

Authors:  W G Laver; G M Air; R G Webster; W Gerhard; C W Ward; T A Dopheide
Journal:  Virology       Date:  1979-10-15       Impact factor: 3.616

2.  Topological mapping of murine leukemia virus proteins by competition-binding assays with monoclonal antibodies.

Authors:  M R Stone; R C Nowinski
Journal:  Virology       Date:  1980-01-30       Impact factor: 3.616

3.  Similar frequencies of antigenic variants in Sendai, vesicular stomatitis, and influenza A viruses.

Authors:  A Portner; R G Webster; W J Bean
Journal:  Virology       Date:  1980-07-15       Impact factor: 3.616

4.  Protein synthesis in Newcastle disease virus-infected chicken embryo cells.

Authors:  L E Hightower; M A Bratt
Journal:  J Virol       Date:  1974-04       Impact factor: 5.103

5.  The mechanism of antigenic drift in influenza viruses: analysis of Hong Kong (H3N2) variants with monoclonal antibodies to the hemagglutinin molecule.

Authors:  R G Webster; W G Laver; G M Air; C Ward; W Gerhard; K L van Wyke
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

6.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

7.  Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies.

Authors:  W G Laver; W Gerhard; R G Webster; M E Frankel; G M Air
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

8.  Hemolytic interaction of Newcastle disease virus and chicken erythrocytes. II. Determining factors.

Authors:  L A Clavell; M A Bratt
Journal:  Appl Microbiol       Date:  1972-03

9.  Antigenic variants of rabies virus.

Authors:  T J Wiktor; H Koprowski
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

10.  Antigenic drift in influenza A viruses. I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies.

Authors:  W Gerhard; R G Webster
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

View more
  9 in total

1.  Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.

Authors:  R M Iorio; R J Syddall; J P Sheehan; M A Bratt; R L Glickman; A M Riel
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Probing the functions of the paramyxovirus glycoproteins F and HN with a panel of synthetic antibodies.

Authors:  Brett D Welch; Marcin Paduch; George P Leser; Zachary Bergman; Christopher A Kors; Reay G Paterson; Theodore S Jardetzky; Anthony A Kossiakoff; Robert A Lamb
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence.

Authors:  C Prehaud; P Coulon; F LaFay; C Thiers; A Flamand
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Monoclonal antibody routinely used to identify avirulent strains of Newcastle disease virus binds to an epitope at the carboxy terminus of the hemagglutinin-neuraminidase protein and recognizes individual mesogenic and velogenic strains.

Authors:  Judith G Alamares; Jianrong Li; Ronald M Iorio
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Fusion mutants of Newcastle disease virus selected with monoclonal antibodies to the hemagglutinin-neuraminidase.

Authors:  R M Iorio; R L Glickman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09

7.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.

Authors:  M Thali; M Charles; C Furman; L Cavacini; M Posner; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  In vitro selection of Junin virus antigenic variants.

Authors:  L E Alché; C E Coto
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.

Authors:  A Sădziene; P A Rosa; P A Thompson; D M Hogan; A G Barbour
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.